ClinicalTrials.gg
RecruitingNCT07224490Updated Jul 13, 2026

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

A Phase 1 interventional study of Kisspeptin 112-121 in Reproductive Disorder, Neurodegeneration and SARS-CoV 2, sponsored by Stephanie B. Seminara, MD. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: Nerve DegenerationReclassifiedWhy we changed it
Registry
Nerve Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. Nerve Degeneration is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Post-Acute COVID-19 Syndrome.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Stephanie B. Seminara, MD · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Planned enrollment
90th of 156
40 · median 53
Started
2026
with 13 others
Phase 1
12 of 195
5 open now
Primary completion
2030-05
later than 79 of 84 live
Registered
182nd of 195
by date

Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 90th largest by planned enrollment of the 156 interventional ones that give a count, is one of 14 that started in 2026, is one of 12 in phase 1, reaches primary completion later than 79 of the 84 other live ones, and was the 182nd registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.

Read the detailed description

Delivery of Interventions:

  • Administration of a single kisspeptin bolus in a dosing range of 0.313 - 13.19 μg/kg
  • Blood sampling before and after administration of kisspeptin (two timepoints total)
03

Conditions studied

  • Reproductive Disorder
  • Neurodegeneration
  • SARS-CoV 2
  • Long COVID

Browse trials for

Keywords

  • Reproductive disorder
  • Neurodegeneration
  • SARS-CoV 2
  • Kisspeptin
  • Long COVID
04

In context

Post-Acute COVID-19 Syndrome Reclassified

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Stephanie B. Seminara, MD is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nerve Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female (ages 18-45 years) or Male (ages 18-60 years)
  • No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate for that particular medication and its method of administration
  • For women, negative serum hCG pregnancy test
  • For cases, diagnosis of post-covid-19 syndrome
  • For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome

Exclusion criteria

Exclusion Criteria

  • Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol or the interpretation of results
  • Active use of illicit drugs (not including marijuana)
  • For women,
  • Pregnant
  • Trying to become pregnant during protocol participation
  • Breast feeding
  • Surgical or natural menopause
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

06

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Kisspeptin administration

    Single bolus of kisspeptin

    Drug: Kisspeptin 112-121

Interventions

07

What researchers measure

Primary outcomes

  1. Difference in mean luteinizing hormone (LH) amplitude between cases and controls

    Difference between cases and controls of mean LH amplitude in response to kisspeptin

    Time frame: Day of study visit (one to two hours)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2030, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2025
First posted
Nov 4, 2025
StartActual
Mar 10, 2026
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07224490
Lead sponsor
Stephanie B. Seminara, MD
Responsible party
Stephanie B. Seminara, MD (Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine, Massachusetts General Hospital) — Sponsor-investigator
First posted
Nov 4, 2025
Start date
Mar 10, 2026
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Jul 13, 2026

Study contacts

Study Coordinator
Contact
MGHKisspeptinResearch@partners.org
617-643-2308

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KISS1 protein, human

Start the discussion